Effect of Avemar® - A fermented wheat germ extract - On rheumatoid arthritis. Preliminary data

G. Bálint, Ágnes Apáthy, Marianne Gaál, Andras Telekes, Ákos Resetár, Gabor Blazsó, G. Falkay, B. Szende, Andras Paksy, Michael Ehrenfeld, Yehuda Shoenfeld, M. Hídvégi

Research output: Article

10 Citations (Scopus)

Abstract

Objective. To investigate the effect of the fermented wheat germ extract (Avemar®) in patients with severe rheumatoid arthritis (RA). Methods. Fifteen female RA (Steinbrocker II-III) patients, who had unsuccesfully tried two different DMARD treatments, were enrolled in an open-label, 1-year long, pilot clinical study. DMARD and steroid therapies were recorded and continued. All patients received Avemar® as additional therapy. For measurement of efficacy the Ritchie Index, the Health Assessment Questionnaire (HAQ) and the assessment of morning stiffness were applied. Patients were evaluated at baseline, 6 and 12 months. For statistical analyses the Wilcoxon test was used. Results. A t both 6 and 12 months, Ritchie index, HAQ and morning stiffness showed significant improvements compared with the baseline values. Dosages of steroids could be reduced in about half of the patients. No side effects of Avemar® were observed. Conclusion. Supple mentation of standard therapies with a continuous administration of Avemar® is beneficial for RA patients.

Original languageEnglish
Pages (from-to)325-328
Number of pages4
JournalClinical and Experimental Rheumatology
Volume24
Issue number3
Publication statusPublished - máj. 2006

Fingerprint

Rheumatoid Arthritis
Antirheumatic Agents
Steroids
Health
Therapeutics
Avemar
Surveys and Questionnaires

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Effect of Avemar® - A fermented wheat germ extract - On rheumatoid arthritis. Preliminary data. / Bálint, G.; Apáthy, Ágnes; Gaál, Marianne; Telekes, Andras; Resetár, Ákos; Blazsó, Gabor; Falkay, G.; Szende, B.; Paksy, Andras; Ehrenfeld, Michael; Shoenfeld, Yehuda; Hídvégi, M.

In: Clinical and Experimental Rheumatology, Vol. 24, No. 3, 05.2006, p. 325-328.

Research output: Article

Bálint, G, Apáthy, Á, Gaál, M, Telekes, A, Resetár, Á, Blazsó, G, Falkay, G, Szende, B, Paksy, A, Ehrenfeld, M, Shoenfeld, Y & Hídvégi, M 2006, 'Effect of Avemar® - A fermented wheat germ extract - On rheumatoid arthritis. Preliminary data', Clinical and Experimental Rheumatology, vol. 24, no. 3, pp. 325-328.
Bálint, G. ; Apáthy, Ágnes ; Gaál, Marianne ; Telekes, Andras ; Resetár, Ákos ; Blazsó, Gabor ; Falkay, G. ; Szende, B. ; Paksy, Andras ; Ehrenfeld, Michael ; Shoenfeld, Yehuda ; Hídvégi, M. / Effect of Avemar® - A fermented wheat germ extract - On rheumatoid arthritis. Preliminary data. In: Clinical and Experimental Rheumatology. 2006 ; Vol. 24, No. 3. pp. 325-328.
@article{02cb839869f14db287a5643a1daec850,
title = "Effect of Avemar{\circledR} - A fermented wheat germ extract - On rheumatoid arthritis. Preliminary data",
abstract = "Objective. To investigate the effect of the fermented wheat germ extract (Avemar{\circledR}) in patients with severe rheumatoid arthritis (RA). Methods. Fifteen female RA (Steinbrocker II-III) patients, who had unsuccesfully tried two different DMARD treatments, were enrolled in an open-label, 1-year long, pilot clinical study. DMARD and steroid therapies were recorded and continued. All patients received Avemar{\circledR} as additional therapy. For measurement of efficacy the Ritchie Index, the Health Assessment Questionnaire (HAQ) and the assessment of morning stiffness were applied. Patients were evaluated at baseline, 6 and 12 months. For statistical analyses the Wilcoxon test was used. Results. A t both 6 and 12 months, Ritchie index, HAQ and morning stiffness showed significant improvements compared with the baseline values. Dosages of steroids could be reduced in about half of the patients. No side effects of Avemar{\circledR} were observed. Conclusion. Supple mentation of standard therapies with a continuous administration of Avemar{\circledR} is beneficial for RA patients.",
keywords = "Avemar{\circledR}, Fermented wheat germ extract, Rheumatoid arthritis",
author = "G. B{\'a}lint and {\'A}gnes Ap{\'a}thy and Marianne Ga{\'a}l and Andras Telekes and {\'A}kos Reset{\'a}r and Gabor Blazs{\'o} and G. Falkay and B. Szende and Andras Paksy and Michael Ehrenfeld and Yehuda Shoenfeld and M. H{\'i}dv{\'e}gi",
year = "2006",
month = "5",
language = "English",
volume = "24",
pages = "325--328",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3",

}

TY - JOUR

T1 - Effect of Avemar® - A fermented wheat germ extract - On rheumatoid arthritis. Preliminary data

AU - Bálint, G.

AU - Apáthy, Ágnes

AU - Gaál, Marianne

AU - Telekes, Andras

AU - Resetár, Ákos

AU - Blazsó, Gabor

AU - Falkay, G.

AU - Szende, B.

AU - Paksy, Andras

AU - Ehrenfeld, Michael

AU - Shoenfeld, Yehuda

AU - Hídvégi, M.

PY - 2006/5

Y1 - 2006/5

N2 - Objective. To investigate the effect of the fermented wheat germ extract (Avemar®) in patients with severe rheumatoid arthritis (RA). Methods. Fifteen female RA (Steinbrocker II-III) patients, who had unsuccesfully tried two different DMARD treatments, were enrolled in an open-label, 1-year long, pilot clinical study. DMARD and steroid therapies were recorded and continued. All patients received Avemar® as additional therapy. For measurement of efficacy the Ritchie Index, the Health Assessment Questionnaire (HAQ) and the assessment of morning stiffness were applied. Patients were evaluated at baseline, 6 and 12 months. For statistical analyses the Wilcoxon test was used. Results. A t both 6 and 12 months, Ritchie index, HAQ and morning stiffness showed significant improvements compared with the baseline values. Dosages of steroids could be reduced in about half of the patients. No side effects of Avemar® were observed. Conclusion. Supple mentation of standard therapies with a continuous administration of Avemar® is beneficial for RA patients.

AB - Objective. To investigate the effect of the fermented wheat germ extract (Avemar®) in patients with severe rheumatoid arthritis (RA). Methods. Fifteen female RA (Steinbrocker II-III) patients, who had unsuccesfully tried two different DMARD treatments, were enrolled in an open-label, 1-year long, pilot clinical study. DMARD and steroid therapies were recorded and continued. All patients received Avemar® as additional therapy. For measurement of efficacy the Ritchie Index, the Health Assessment Questionnaire (HAQ) and the assessment of morning stiffness were applied. Patients were evaluated at baseline, 6 and 12 months. For statistical analyses the Wilcoxon test was used. Results. A t both 6 and 12 months, Ritchie index, HAQ and morning stiffness showed significant improvements compared with the baseline values. Dosages of steroids could be reduced in about half of the patients. No side effects of Avemar® were observed. Conclusion. Supple mentation of standard therapies with a continuous administration of Avemar® is beneficial for RA patients.

KW - Avemar®

KW - Fermented wheat germ extract

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=33746586489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746586489&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 325

EP - 328

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3

ER -